APhA Urges FDA to Prioritize Patient Safety in Peptide Review

On July 17, 2026, the American Pharmacists Association submitted formal comments to the FDA and its Pharmacy Compounding Advisory Committee ahead of the committee's July 23-24 meeting on whether seven peptides should be added to the Section 503A Bulks List. APhA's message was direct: as demand for peptide products keeps climbing, patient safety, scientific evidence, and regulatory oversight need to come first. The organization pointed to a growing black and gray market where peptides are sold online through channels that sidestep standard regulatory safeguards, exposing buyers to real risks including contamination, inaccurate dosing, and counterfeit ingredients.

In its comments, APhA specifically flagged the risks of buying peptides from unregulated online sellers: contamination, inaccurate dosing, counterfeit ingredients, and serious adverse health consequences for people who use them without medical supervision. At the same time, the organization was careful not to call for a blanket ban. Because pharmacists currently lack sufficient peer-reviewed evidence to confidently counsel patients on many of the nominated peptides, including their effectiveness, safety profiles, and long-term effects, APhA supports the FDA's own recommendation not to add these substances to the Section 503A Bulks List at this time. Instead, the group is pushing for more rigorous research, stronger education for patients and providers, and closer coordination between FDA, state pharmacy boards, and the U.S. Pharmacopeia to raise oversight and quality standards across the board.

APhA's letter lands at a pivotal moment. Peptide sales have surged across wellness, longevity, and performance circles over the past two years, often outpacing the clinical evidence and regulatory clarity needed to support that growth. Pharmacists are on the front lines of this shift: patients increasingly ask about peptides they found online, and pharmacists say they often cannot verify what is actually in the product, how it was manufactured, or whether it was tested by an independent lab. That gap between consumer demand and verifiable quality is exactly what regulatory bodies like the FDA and organizations like APhA are trying to close, and it is the same gap that third-party testing and Certificates of Analysis are designed to address at the sourcing level.

Whatever the FDA decides on July 23-24, APhA's core point stands: the way to reduce risk is verified quality, not guesswork. At Kynetide, every peptide in our catalog ships with a batch-specific third-party Certificate of Analysis confirming 99%+ HPLC purity, so labs can see exactly what they are working with before an experiment begins. That same documentation is what allows research protocols to be reproduced accurately from one lab to the next, which is the whole point of rigorous science. As always, our products are intended strictly for laboratory research use and are not approved for human or animal use.

The Section 503A Bulks List is the FDA's roster of bulk drug substances that compounding pharmacies are allowed to use when preparing customized medications for individual patients. The FDA's Pharmacy Compounding Advisory Committee reviews nominated substances, including peptides, and makes recommendations on whether each one meets the safety and evidence standards needed for inclusion. Being left off the list does not make a peptide illegal to research; it simply means pharmacies cannot compound it into a patient-ready drug product until more clinical evidence is available.

No. Kynetide does not compound or sell finished pharmaceutical products intended for patient use, and nothing in our catalog is dispensed through a pharmacy. What we offer is a line of 99%+ HPLC-pure research peptides, each backed by a batch-specific third-party Certificate of Analysis, made for laboratories studying receptor biology, formulation science, and related peptide chemistry. As with all Kynetide products, these compounds are intended strictly for laboratory research use and are not approved for human or animal use.